Cabaletta Bio Inc. (CABA)
XMEX 
NASDAQ (NGS) Primary XMEX Summary
CABA Chart
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Cabaletta Bio Inc. (CABA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cabaletta Bio Inc. ever had a stock split?
Cabaletta Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | Steven A. Nichtberger CEO | XMEX Exchange | US12674W1099 ISIN |
| US Country | 156 Employees | - Last Dividend | - Last Split | 25 Oct 2019 IPO Date |
Overview
Cabaletta Bio, Inc. is a forward-thinking clinical-stage biotechnology company that has dedicated its efforts towards the discovery and development of cutting-edge engineered T cell therapies, specifically targeting B cell-mediated autoimmune diseases. Founded in 2017 and evolving from its original name, Tycho Therapeutics, Inc., to Cabaletta Bio, Inc. in August 2018, the company has established its headquarters in Philadelphia, Pennsylvania. Through strategic collaborations with prestigious institutions such as the University of Pennsylvania, the Children's Hospital of Philadelphia, along with industry partnerships with Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc., Cabaletta Bio is at the forefront of innovative treatments for autoimmune diseases. These collaborations bolster the company’s research, development, and potential commercialization of its therapies.
Products and Services
- CABA-201: As the lead product candidate, CABA-201 is a pioneering fully human anti-CD19 binder undergoing Phase 1/2 clinical trials. This therapy is being developed for multiple B cell-mediated autoimmune diseases, including dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. CABA-201 represents Cabaletta's commitment to addressing a range of debilitating diseases through a single therapeutic approach.
- DSG3-CAART: Currently in Phase I/II clinical trial, DSG3-CAART is an innovative cell therapy designed to treat patients with mucosal pemphigus vulgaris, a rare and severe autoimmune blistering disease of the mucous membranes. By targeting the specific cause of this condition at the cellular level, DSG3-CAART holds the promise of delivering targeted and effective relief to those suffering from this challenging disease.
- MuSK-CAART: Another investigational cell therapy in Cabaletta’s pipeline is MuSK-CAART, which has progressed to Phase I/II clinical trial stages for the treatment of patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. This condition, characterized by muscle weakness and fatigue, represents a critical area of unmet medical need that Cabaletta Bio seeks to address through its targeted T cell therapy approach.
